Spring direct naar de hoofdnavigatie of de inhoud
‘In the end it's all about the value that the patent adds to the product.’
Mark Einerhand

Mark Einerhand

  • Life Sciences
  • European and Dutch Patent Attorney
  • Partner

Mark Einerhand has been active in the patent world since 1998, when he made the switch from a biotech startup to V.O.

Mark’s career started in science. After his studies of molecular biology at the University of Amsterdam, he took his PhD in medical science inLeiden, in 1992. He was a visiting scientist at Cornell University in New York and the MRC at Mill Hill in London.

Continue reading

His particular expertise lies in the field of medical (bio)technology, diagnostics and medicines. Because of his background at Introgene/Crucell, Mark has a special affinity with Life Science startups. He has a wide experience in patent cases before the court in The Hague.

Working experience

  • Patent Attorney, V.O. (1998-present)
  • IntroGene (now Crucell), Rijswijk (1995)
  • Post-Doc at Leiden University (1993)
  • Medical Research Council, Mill Hill, London (1992)
  • Visiting Scientist, Cornell University New York (1992)

Education

  • PhD in Medicine, Leiden University (1992)
  • MSc in Biochemistry, University of Amsterdam (1987), Major in Molecular Oncology, Dutch Cancer Institute

Publications

  • Co-author of article ‘The patentability of stem cells in Europe’, IAM Life Sciences 2015.
    Einerhand, M.P.W. (2011): Advance offering of generics found to infringe. Managing Intellectual Property: Vol 205: page: 87.
  • Einerhand M.P.W. (2010): A contribution to: Legal and intellectual property issues associated with stem cells. In: Stem Cells; scientific facts and fiction, (C. Mummery; I. Wilnut, A van de Stolpe and
    B.A.J. Roelen), Academic Press: Elsevier.
  • Einerhand M.P.W. and van Melle, J (2004): Patenting of inventions in the field of bio-informatics.
    In: The new avenues in Bioinformatics, (Seckbach, J and Rubin, E eds), Kluwer Academic Publishers, the Netherlands.
  • Principle inventor on Patents and Patent Applications: Einerhand, M.P.W. and Valerio (1997). WO 98/32870: US 6,232,105: A conditional replication and expression system. Einerhand, M.P.W. and Valerio (1997). WO 99/32647: Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into chromosomal DNA of target cells in gene therapy. Einerhand, M.P.W. and Valerio (1996). WO98/24924: NZ 336185:
  • Transduction of primate hemopoietic repopulating stem cells. Einerhand, M.P.W. and Valerio (1995). WO 97/20943: US 6,140,103: Regulated protein expression in stably transfected mammalian cells. Einerhand, M.P.W. (1992) Gene transfer into hemopoietic stem cells: prospects for human gene therapy. University of Leiden.

Professional & Community Activities

  • Member of the Steering Committee World IP Forum 2015
    Former member of the European Qualifying Examination committee III

Languages

  • English
  • Dutch
  • German

Also see these experts

Annemiek Tepper

Annemiek Tepper

  • European and Dutch Patent Attorney, European Patent Litigator
  • Partner
Jetze Beeksma

Jetze Beeksma

  • European and Dutch Patent Attorney, European Patent Litigator
  • Partner
More experts

News

Coastruction: repairing nature with 3D artificial reefs

Help restore damaged reefs with 3D printed artificial reefs. That’s Coastruction’s mission. Not for nothing did this ambitious startup receive the prestigious V.O. Patents & Trademarks Innovation Award during the NL Startup Competition. We spoke with Josine Beets, Project & Business Development Manager at Coastruction.Continue reading

What about your ‘T & C’?

The importance of terms and conditions is often underestimated – writing the two words in full is sometimes even too much. “Who reads them at all?”, ‘We don’t even know what’s in them ourselves’, ‘We rarely fall back on them’ and ‘Why would we want to put general terms and conditions forward if the cooperation […]Continue reading

Upcoming decision on legal criterion for ‘novelty’

One of the most important requirements for obtaining a patent on a product in Europe is that the product is novel. That means that before the day on which the patent application was filed, the product was not yet available to the public in any way.Continue reading

Events

NL Startup Competition 2025

3089 JB Rotterdam, Netherlands

In April and May the second edition of NL Startup Competition, organized by Erasmus Enterprises, will take place. An extraordinary opportunity for innovative talents who take up the challenge to pitch their startup for prize money, a valuable network and knowledge.

Continue reading